DNA Stock Overview
Develops platform for cell programming in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Ginkgo Bioworks Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.22 |
| 52 Week High | US$72.00 |
| 52 Week Low | US$5.26 |
| Beta | 1.17 |
| 1 Month Change | 28.55% |
| 3 Month Change | 26.33% |
| 1 Year Change | -85.57% |
| 3 Year Change | -97.15% |
| 5 Year Change | n/a |
| Change since IPO | -97.48% |
Recent News & Updates
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 15
Ginkgo Bioworks: Not Enough Progress
Nov 13Recent updates
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 15Ginkgo Bioworks: Not Enough Progress
Nov 13Revenues Tell The Story For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) As Its Stock Soars 33%
Oct 04Ginkgo Bioworks: Here Comes The Test
Aug 22The Price Is Right For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Even After Diving 27%
Aug 16Ginkgo Bioworks: Losing A Major Supporter
Jun 25Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 47% Slump
Jun 18Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
May 11Ginkgo Bioworks: Broken Narrative
May 10Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
Apr 26Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts
Mar 06With Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) It Looks Like You'll Get What You Pay For
Mar 01Ginkgo Bioworks: More Awful Revenue Guidance
Mar 01Ginkgo Bioworks At The Intersection Of Cutting-Edge Technology And Financial Disappointment
Jan 26Ginkgo Bioworks: Strategic Shifts Amidst Financial Uncertainty
Dec 20Ginkgo Bioworks: A Long Way To Go
Nov 21News Flash: 9 Analysts Think Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Earnings Are Under Threat
Nov 13Ginkgo Bioworks: More Revenue Issues
Nov 13Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 30% Slump
Nov 10Porter's 5 Forces Suggest That Ginkgo Is A Buy
Oct 25Ginkgo Bioworks: Products Progressing Towards Market
Oct 10Ginkgo Bioworks: Google Partnership Increases Runway (Rating Upgrade)
Aug 30Ginkgo Bioworks: Lack Of Progress Is A Concern
Aug 18Ginkgo Bioworks: Major Revenue Trouble (Ratings Downgrade)
Aug 10Ginkgo Bioworks: Tremendous Potential, But Strong Short Term Headwinds
Jun 23Ginkgo Bioworks: Avoid For Now
Feb 20Ginkgo: Standardizing Offerings For Growth
Feb 08Ginkgo Bioworks: Increasing Focus On Pharma And Biotech
Jan 12Shareholder Returns
| DNA | US Chemicals | US Market | |
|---|---|---|---|
| 7D | 16.9% | 1.4% | 2.8% |
| 1Y | -85.6% | -3.4% | 24.5% |
Return vs Industry: DNA underperformed the US Chemicals industry which returned -3.4% over the past year.
Return vs Market: DNA underperformed the US Market which returned 24.5% over the past year.
Price Volatility
| DNA volatility | |
|---|---|
| DNA Average Weekly Movement | 14.3% |
| Chemicals Industry Average Movement | 5.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DNA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: DNA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,218 | Jason Kelly | www.ginkgobioworks.com |
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Ginkgo Bioworks Holdings, Inc. Fundamentals Summary
| DNA fundamental statistics | |
|---|---|
| Market cap | US$497.38m |
| Earnings (TTM) | -US$651.19m |
| Revenue (TTM) | US$217.95m |
2.5x
P/S Ratio-0.8x
P/E RatioIs DNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DNA income statement (TTM) | |
|---|---|
| Revenue | US$217.95m |
| Cost of Revenue | US$41.54m |
| Gross Profit | US$176.41m |
| Other Expenses | US$827.60m |
| Earnings | -US$651.19m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -12.27 |
| Gross Margin | 80.94% |
| Net Profit Margin | -298.78% |
| Debt/Equity Ratio | 0% |
How did DNA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 23:01 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ginkgo Bioworks Holdings, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Derik de Bruin | BofA Global Research |
| Michael Ryskin | BofA Global Research |
| Mark Massaro | BTIG |